BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

18 articles for AD Borthwick

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.EBI
Glaxosmithkline
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.EBI
Glaxosmithkline
Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs.EBI
Glaxosmithkline
The discovery of GSK221149A: a potent and selective oxytocin antagonist.EBI
Glaxosmithkline
Oral oxytocin antagonists.EBI
Drugmoldesign
Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs.EBI
Glaxosmithkline
Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.EBI
Glaxosmithkline
2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.EBI
Cardiovascular and Urogenital Centre of Excellence For Drug Discovery
Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability.EBI
Glaxosmithkline
Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: potency and plasma stability.EBI
Glaxosmithkline
Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality.EBI
Glaxosmithkline
Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 1. The alpha-methyl-trans-lactam template.EBI
Glaxo Wellcome Research and Development
Discovery and lead optimisation of a potent, selective and orally bioavailable RARĪ² agonist for the potential treatment of nerve injury.EBI
King'S College
Design and synthesis of monocyclic beta-lactams as mechanism-based inhibitors of human cytomegalovirus protease.EBI
Glaxo Wellcome Research and Development
Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.EBI
King'S College
Isoquinoline derivatives and use thereofBDB
Purdue Pharma
Pyrimidine compounds as JAK kinase inhibitorsBDB
Theravance Biopharma R&D Ip
Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.BDB
Banyu Tsukuba Research Institute